Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced on March 30, 2026, that it has entered into a securities purchase agreement for a private placement of 6,130,000 shares of its ordinary shares at a price of $3.25 per share. The transaction is expected to generate approximately $20.2 million in gross proceeds before deducting offering fees and expenses. The private placement is anticipated to close on March 31, 2026, subject to customary closing conditions. The funds raised will be utilized to support the research and development of the company's clinical-stage product candidates, as well as for working capital and other general corporate purposes. This financing is expected to extend the company's cash runway into the second half of 2027, providing a significant boost to its operational capabilities. The placement was led by Panacea Venture, with participation from other existing and new healthcare-focused investors. Leerink Partners LLC and Cantor Fitzgerald & Co. are acting as joint placement agents for the offering. The company plans to file a registration statement with the SEC within 45 days after the closing to register the resale of the shares. This strategic move is seen as a positive step for Connect Biopharma, as it aims to enhance its financial stability and continue advancing its innovative therapies in the competitive biopharmaceutical landscape.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.